Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Perrigo, Apotex Sued by Meda Over Generic Astepro Spray

Generic drugmakers Perrigo Co. and Apotex Inc. were sued by Meda Pharmaceuticals Inc. and accused of infringing a U.S. patent for the nasal spray Astepro, used to treat allergies.

Meda, based in Somerset, New Jersey, contends Perrigo, based in Allegan, Michigan, and Apotex, of Toronto, plan to market copies of the drug before its U.S. patent expires in 2028. It filed a complaint Jan. 19 in federal court in Trenton, New Jersey.

“Perrigo is committed to making quality health care more affordable for our customers,” Chief Executive Officer Joseph C. Papa said today in a statement.

An Apotex spokesman, Elie Betito, didn’t immediately reply to voice and e-mail messages seeking comment on the lawsuit.

Meda is a unit of Solna, Sweden-based Meda AB.

The case is Meda v. Apotex, 12-cv-361, U.S. District Court, District of New Jersey (Trenton).

To see the patent, click: 8,071,073

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.